Knokke-Heist (Belgium), 9 December 2024, 6:00 a.m.; bonyf NV (Mnemonic: MLBON), the next-generation oral comfort expert, is a Euronext Paris listed company and specializes in the development, production, and marketing of oral, denture, orthodontic, and wound care products. As a leader in dental care innovation, bonyf is committed to advancing oral health solutions that enhance patient well-being. Today, the company is pleased to announce a significant milestone: the successful certification of NitrAdine^® Disinfecting Tablets under the stringent European Union’s Medical Device Regulation (MDR), marking a new chapter in its pursuit of excellence.

bonyf’s R&D team is excited to have obtained the MDR certification for its portfolio of medical devices. This achievement reflects the company’s ongoing commitment to meeting the highest standards of quality, safety, and performance in the dental and denture care sectors. The MDR certification is a rigorous process, ensuring that each product complies with the European Union’s stringent requirements for medical devices, providing consumers with the assurance that bonyf’s products are safe and reliable for use in healthcare settings.

“We are thrilled to have achieved this certification, which demonstrates our ongoing commitment to innovation, quality, and patient safety”, said Jean-Pierre Bogaert, CEO of bonyf group. “This accomplishment not only opens new market opportunities within Europe but also reinforces our position as a trusted leader in the oral care and medical device industry.”

As part of its ongoing commitment to research and development, bonyf will continue to enhance its product offerings, integrating the latest scientific advancements with user-centric designs to address the evolving needs of oral care professionals and their patients.

For more information, visit bonyf.com or contact investor@bonyf.com.

bonyf’s strengths

• Products with patented formulations
• Produced in Switzerland compliant with stringent international quality regulations
• Proven clinical efficacy
• Commercial presence in 37 countries
• Prospects for solid growth and rapid profitability
• A fast-growing oral and dental care market